Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …

A major unanswered question in the dementia field is whether cognitively unimpaired
individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is …

The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease
emphasises the need for consensus recommendations on the rational use of biomarkers to …

PET, CSF and plasma biomarkers of tau pathology may be differentially associated with
Alzheimer's disease (AD)‐related demographic, cognitive, genetic and neuroimaging …

The advent of PET ligands that bind tau pathology has enabled the quantification and
visualization of tau pathology in aging and in Alzheimer disease (AD). There is strong …

Purpose Positron emission tomography (PET) with the first and only tau targeting radiotracer
of 18F-flortaucipir approved by FDA has been increasingly used in depicting tau pathology …

The detection and staging of Alzheimer's disease (AD) using non-invasive imaging
biomarkers is of substantial clinical importance. Positron emission tomography (PET) …

Background and Objectives: The US Food and Drug Administration (FDA) defines a
biomarker as a characteristic that is measured as an indicator of normal biological …

Abstract Purpose In 2017, the Geneva Alzheimer's disease (AD) strategic biomarker
roadmap initiative proposed a framework of the systematic validation AD biomarkers to …

The recent development of several tau positron emission tomography (PET) tracers
represents a major milestone for the Alzheimer's disease (AD) field. These tau PET tracers …